Home Blog Page 151

Aircastle Limited (NYSE:AYR)

0

Headline: The organization has a place with Services part and Rental & Leasing Services industry. Shares of AYR finished Tuesday session in green in the midst of unstable exchanging.

Exchanging Updates: Aircastle Limited (NYSE:AYR) went up 2.37% amid exchanging on 20/05/2016, with the organization’s shares hitting the cost close $21.60 on dynamic exchanging volume of 298,500.00 looked at its three months normal exchanging volume of 278,272.00. The firm is currently exchanging -0.75% low its 20 day moving normal, SMA 50 of 2.80% and a SMA 200 of 4.36%. AYR stock opened its last exchange at $21.27 and after moving in an extent of $21.18 to $21.87.

Stock enlisted one year high at $22.99% and the one year low of 15.06%. AYR stock’s cost is currently -4.95% up from its 52-week high and 50.21% up from its 52-week low. AYR institutional possession is held at 66.80% while insider proprietorship was 0.60%.

News: Aircastle Limited (the “Organization” or “Aircastle”) (AYR) reported that Sin Jin Lim and Tom Gathercole will join the Company’s airline coverage group in January 2017 and will be situated in Singapore and Dublin, Ireland, individually.

Mr. Lim conveys to Aircastle a quarter century in the air ship renting industry, including broad specialized and advertising aptitude. Preceding joining Aircastle, he worked with GECAS. Mr. Gathercole joins Aircastle from Avolon, where he was a legal counselor and had critical business arrangement experience and exchange execution obligations all through the Europe, Middle East and Africa area.

Conor Stafford, Aircastle’s EVP of Leasing, expressed, “I’m pleased to welcome Sin Jin and Tom to the Aircastle group. They offer vitality, development and a solid expertise set as a powerful influence for our rent position and new venture exercises, and I’m certain they will extend our capacities and reach in Asia and the EMEA districts.”

Orthofix International NV (NASDAQ:OFIX)

0

Headline: The organization has a place with Healthcare  part and Medical Appliances & Equipment industry. Shares of OFIX finished Monday session in green/red in the midst of unstable exchanging.

Exchanging Updates: Orthofix International NV (NASDAQ:OFIX) went up 0.61% amid exchanging on 12/19/2016, with the organization’s shares hitting the cost close $34.77 on dynamic exchanging volume of 562,180.00 looked at its three months normal exchanging volume of 155,196.00. The firm is currently exchanging -8.32% low its 20 day moving normal, SMA 50 of -8.82% and a SMA 200 of 17.68%. OFIX stock opened its last exchange at $34.83 and after moving in an extent of $34.56 to $35.76.

Stock enlisted one year high at $48.25% and the one year low of 32.51%. OFIX stock’s cost is currently -27.94% down from its 52-week high and 6.95% up from its 52-week low. OFIX institutional possession is held at 97.80% while insider proprietorship was 3.20%.

News: Orthofix International N.V. (OFIX), an expanded, worldwide therapeutic gadget organization, as of late pronounced that Alexis V. Lukianov has been named to its Board of Directors. Mr. Lukianov’s arrangement grows the Board to 10 executives, 9 of whom are autonomous chiefs.

With over 30 years’ understanding, and a broad foundation in orthopedics, Mr. Lukianov has held senior official positions with organizations, for example, Medtronic SofamorDanek and Smith and Nephew Orthopedics, where he was the chief of a specialty unit that conveyed appendage stretching innovation to the United States from Russia. He was the originator of and served as the Chairman of the Board and CEO of BackCare Group, Inc., a spine doctor rehearse organization, and from 1999-2015, Mr. Lukianov served as the Chairman and CEO at NuVasive, Inc.

“We are cheerful that Alex Lukianov will join our Board of Directors. As a senior rehearsed official in the med-tech industry, Alex will be an esteemed arranged member as we keep on focusing on building up our development openings,” said Ron Matricaria, Chairman of the Board.

A business person, Mr. Lukianov has served on different open, private and not-revenue driven sheets tallying the Volcano Corporation, the California Health Institute, BIOCOM, and the Medical Device Manufacturers Association (MDMA).

Milestone Scientific Inc. (NYSEMKT:MLSS)

0

Headline: The organization has a place with Healthcare part and Medical Instruments & Supplies industry. Shares of MLSS finished Monday session without any change in the midst of unstable exchanging.

Exchanging Updates: Milestone Scientific Inc. (NYSEMKT:MLSS) remained flat amid exchanging on 12/19/2016, with the organization’s shares hitting the cost close $1.30 on dynamic exchanging volume of 55,664.00 looked at its three months normal exchanging volume of 22,997.00. The firm is currently exchanging -23.19% low its 20 day moving normal, SMA 50 of -27.81% and a SMA 200 of -40.68%. MLSS stock opened its last exchange at $1.35 and after moving in an extent of $1.30 to $1.40.

Stock enlisted one year high at $3.20% and the one year low of 1.15%. MLSS stock’s cost is currently -59.37% down from its 52-week high and 13.04% up from its 52-week low. MLSS institutional possession is held at 3.20% while insider proprietorship was 10.70%.

News: Milestone Scientific Inc. (NYSE MKT: MLSS), a medicinal R&D and dental items organization that outlines, licenses, broods and markets a developing arrangement of imaginative remedial infusion advancements, as of late pronounced the estimating of an endorsed open offering of 2,000,000 shares of its regular stock and going with warrants to buy 1,500,000 shares. Every share of normal stock is sold in mix with a warrant to buy 0.75 shares of regular stock. General society offering cost for every share and related warrant is $1.50. The warrants have a three-year term and a practice cost of $2.55 per share. The gross continues to the organization from this offering are relied upon to be about $3,000,000, before deducting endorsing rebates and commissions and other assessed offering costs. The organization has conceded the delegate of the guarantors a 45-day over-portion choice to buy up to an extra 300,000 shares of its regular stock or potentially 225,000 warrants. The offering is relied upon to close on December 21, 2016, subject to standard shutting conditions.

Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI)

0

Headline: The organization has a place with Heathcare part and Biotechnology industry. Shares of BCLI finished monday session in green in the midst of unstable exchanging.

Exchanging Updates: Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) went up 7.87% amid exchanging on 12/19/2016, with the organization’s shares hitting the cost close $2.88 on dynamic exchanging volume of 1.98M looked at its three months normal exchanging volume of 234,720.00. The firm is currently exchanging 29.38% over its 20 day moving normal, SMA 50 of 28.20% and a SMA 200 of 20.21%. BCLI stock opened its last exchange at $3.04 and after moving in an extent of $2.76 to $3.08.

Stock enlisted one year high at $3.87% and the one year low of 1.90%. BCLI stock’s cost is currently -25.58% down from its 52-week high and 51.58% up/down from its 52-week low. BCLI institutional possession is held at 9.20% while insider proprietorship was 0.30%.

News: Brainstorm Cell Therapeutics Inc. (BCLI), a main engineer of grown-up immature microorganism advances for neurodegenerative ailments, as of late offered a corporate overhaul and proclamed its clinical improvement goals for 2017.

2017 Aims and Objectives

  • Start a global Phase 3 trial with NurOwn® in ALS
  • Accommodation of Application for Hospital Exemption for NurOwn® in Israel
  • Effective End of Phase 2 Meeting

Brainstorm as of late expert a fruitful End-of-Phase 2 Meeting with the United States Food and Drug Administration (FDA). Brainstorm has achieved general concurrence with the FDA to continue to a Phase 3 trial. Significantly, the FDA has acknowledged the key components of the Phase 3 program to bolster a Biologic License Application (BLA) for NurOwn® in ALS. The arranged Phase 3 clinical trial will be a randomized, twofold visually impaired, fake treatment controlled multi-measurement trial that will be led at different locales in the U.S. what’s more, in Israel. The trial is required to start enlisting patients in the second quarter of 2017.

“We are exceptionally content with the result of the End-of-Phase 2 meeting with the FDA, and we anticipate starting our Phase 3 clinical trial for NurOwn® in ALS,” said Chaim Lebovits, BrainStorm’s President and Chief Executive Officer. “Together with our clinical specialists in the U.S. furthermore, Israel, we have worked constantly with the FDA to progress NurOwn® through to late-organize improvement. Working off NurOwn’s wellbeing and clinical viability saw to date, we are building up a Phase 3 program that, if effective, will position us to convey to the market a creative, ailment changing treatment for patients experiencing ALS.”

Brainstorm to Apply for Hospital Exemption for NurOwn® in Israel

Brainstorm arrangements to present an application in Israel that will permit understanding access to NurOwn® as a treatment that has been allowed Hospital Exemption. This as of late endorsed pathway would allow Brainstorm to collaborate with a medicinal focus in Israel and be permitted to treat patients with NurOwn® for a charge.

Doctor’s facility Exemption takes into account propelled treatment restorative items to be made accessible to a gathering of patients to be settled upon by the Israeli Ministry of Health. It is expected to furnish patients with the likelihood to profit by a specially designed, creative, singular treatment where there is a basic neglected need and a nonattendance of legitimate helpful choices. The treatment is normally a specially designed item, for example, NurOwn®, fabricated utilizing a patient’s own particular cells that are set up on a non-routine premise. So as to meet all requirements for a Hospital Exemption, various vital criteria must be met tallying readiness as indicated by particular quality guidelines (proportional to those for an authorized item), use in a healing center and use under the restrictive obligation of a medicinal specialist.

“Our arranged application for Hospital Exemption is our initial move toward furnishing ALS patients with access to NurOwn,” said Mr. Lebovits. “Our choice to continue with this application depends on a solid intrigue voiced by ALS patients by means of a survey. We predict conceivable medicines under this pathway as ahead of schedule as the second 50% of 2017.”

Phone call and Webcast Details:

Brainstorm will have a phone call and live webcast, as of late, Monday December nineteenth, at 8.30am Eastern Time. The call will be led in English.

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV)

0

Headline: The organization has a place with Healthcare part and Biotechnology industry. Shares of CTRV finished Monday session in red in the midst of unstable exchanging.

Exchanging Updates: ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) went down -6.32% amid exchanging on 12/19/2016, with the organization’s shares hitting the cost close $1.78 on dynamic exchanging volume of 1.24M looked at its three months normal exchanging volume of 757,738.00. The firm is currently exchanging -11.68% low its 20 day moving normal, SMA 50 of -0.19% and a SMA 200 of 38.27%. CTRV stock opened its last exchange at $1.89 and after moving in an extent of $1.64 to $1.89.

Stock enlisted one year high at $2.65% and the one year low of 0.76%. CTRV stock’s cost is currently -32.83% down from its 52-week high and 134.21% up from its 52-week low. CTRV institutional possession is held at 0.33% while insider proprietorship was 0.20%.

News: ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical organization concentrated on advancement and commercialization of focused antiviral treatments, as of late pronounced that tenofovir exalidex (some time ago called CMX157), the Company’s strong prodrug simple of tenofovir, showed raised antiviral action at the most astounding arranged measurement of 100 mg in the continuous Phase 2a numerous climbing dosage clinical trial of tenofovir exalidex (TXL) in patients with HBV. This straight on trial contrasting TXL with tenofovir disoproxil fumarate (TDF, Gilead’s Viread®) is the main assessment of TXL in constantly contaminated hepatitis B (HBV) patients. ContraVir arrangements to start assessing TXL at 150 mg for every day dosing and possibly higher dosing in view of TXL’s proceeded with solid execution, to date, and taking after late freedom by the autonomous information wellbeing checking board (DSMB).

“We are content with the antiviral profile that is being displayed by TXL at this first stage in our clinical assessment of this medication in HBV patients,” said James Sapirstein, CEO of ContraVir. “TXL has demonstrated a fantastic security profile, and we are supported that as we go to higher dosages over 100 mg we may see considerably more prominent antiviral movement with a proceeded with amazing wellbeing profile. We think exhibiting this exceptional profile for TXL may open numerous entryways as far as growing new mix treatments for HBV that have remedial potential.”

Lannett Company, Inc. (NYSE:LCI)

0

Headline: The organization has a place with Healthcare part and Drugs – Generic industry. Shares of LCI finished Monday session in green in the midst of unstable exchanging. As

Exchanging Updates: Lannett Company, Inc. (NYSE:LCI) went up 1.68% amid exchanging on 12/19/2016, with the organization’s shares hitting the cost close $24.20 on dynamic exchanging volume of 850,865.00 looked at its three months normal exchanging volume of 1.16M. The firm is currently exchanging 3.54% over its 20 day moving normal, SMA 50 of 6.41% and a SMA 200 of -1.85%. LCI stock opened its last exchange at $23.70 and after moving in an extent of $23.45 to $24.75.

Stock enlisted one year high at $44.49% and the one year low of 16.75%. LCI stock’s cost is currently -45.61% down from its 52-week high and 44.48% up from its 52-week low. LCI institutional possession is held at 80.70% while insider proprietorship was 14.10%.

News: Lannett Company, Inc. (LCI) as of late announced that it got endorsement from the U.S. Nourishment and Drug Administration (FDA) of its Supplemental New Drug Application (sNDA) for Morphine Sulfate Oral Solution CII, shading and flavor included, 20 mg/mL. As per IMS, add up to U.S. deals for the 12 months finished October 2016 of Morphine Sulfate Oral Solution, at Average Wholesale Price (AWP) were about $22 million.

“This supplemental endorsement permits us to augment our Morphine Sulfate Oral Solution offering with an item that is favored by a key portion of the market,” said Arthur Bedrosian, CEO of Lannett. “Adding shading to Morphine Sulfate Oral Solution is a component essential to human services suppliers and the option of enhancing specialists makes the medicine more tasteful for patients. We envision propelling our Morphine Sulfate Oral Solution CII, the eleventh item endorsement we have gotten in schedule 2016, in the blink of an eye. Our item will be accessible in adjusted containers and incorporate an aligned oral apportioning gadget.”

Morphine Sulfate Oral Solution is an opioid agonist showed for the organization of intense and endless torment in opioid-tolerant patients sufficiently extreme to require an opioid pain relieving and for which elective medicines are deficient.

Starwood Property Trust, Inc. (NYSE:STWD)

0

Headline: The organization has a place with financials part and REIT – Diversified industry. Shares of STWD finished Monday session in green in the midst of unstable exchanging.

Exchanging Updates: Starwood Property Trust, Inc. (NYSE:STWD) went up 1.74% amid exchanging on 12/19/2016, with the organization’s shares hitting the cost close $22.28 on dynamic exchanging volume of 1.93M looked at its three months normal exchanging volume of 3.07M. The firm is currently exchanging 0.02% over its 20 day moving normal, SMA 50 of 1.03% and a SMA 200 of 8.34%. STLD stock opened its last exchange at $21.99 and after moving in an extent of $21.97 to $22.29.

Stock enlisted one year high at $23.46% and the one year low of 16.69%.STLD stock’s cost is currently -3.02% down from its 52-week high and 43.25% up/down from its 52-week low. STLD institutional possession is held at 68.30% while insider proprietorship was 1.50%.

News: Starwood Property Trust, Inc. (STWD) (the “Organization”) pronounced as of late that it has shut another $300 million four-year secured term advance and another $100 million four-year secured rotating credit office. The Company likewise has as of late fulfilled obligation and value offerings totaling over $1.1 billion, including an upsized private offering of $700 million of 5% unsecured senior notes due 2021 and a typical stock issuance with net continues of $448.1 million.

“We are excited to have invigorated our accounting report through our late capital markets exercises which have the advantages of expanding our liquidity, developing the tenor of our financings and unencumbering a noteworthyportion of our benefits. Critically, we effectively got to the unsecured senior obligation showcases without precedent for our Company’s history, highlighting the quality of our credit profile and opening an extra wellspring of financing going ahead,” expressed Barry Sternlicht, Chairman and Chief Executive Officer of Starwood Property Trust. “This extra capital will permit us to keep on investing over our business portions, where we have a hearty worldwide pipeline of alluring open doors. With over $9.3 billion of obtaining limit, we are all around situated to keep on executing on our procedure of sourcing the best hazard balanced returning speculations while utilizing unassuming budgetary influence, to make steady and developing aggregate returns for our shareholders.”

The Company will utilize a bit of the returns from the new term advance, together with continues from the late issuance of unsecured notes, to reimburse in full the current term advance, which, as of September 30, 2016, had about $653.2 million remarkable. The adjust of the returns will be utilized for speculations as a part of our objective resources, the installment of liabilities and other working capital needs. The Company does not expect to draw on the rotating credit office immediately.

BofI Holding, Inc. (NASDAQ:BOFI)

0

Headline: The organization has a place with Financials part and Banks industry. Shares of BOFI finished Monday session in green in the midst of unstable exchanging.

Exchanging Updates: BofI Holding, Inc. (NASDAQ:BOFI) went up 3.37% amid exchanging on 19/12/2016, with the organization’s shares hitting the cost close $28.26 on dynamic exchanging volume of 1.10M looked at its three months normal exchanging volume of 1.20M. The firm is currently exchanging 10.43% over its 20 day moving normal, SMA 50 of 22.60% and a SMA 200 of 39.76%. BOFI stock opened its last exchange at $27.63 and after moving in an extent of $27.61 to $28.57.

Stock enlisted one year high at $29.24% and the one year low of 13.47%.BOFI stock’s cost is currently -3.35% down from its 52-week high and 109.80% up from its 52-week low. BofI Holding, Inc. (NASDAQ:BOFI) institutional possession is held at 91.70% while insider proprietorship was 5.90%.

News: Bank of Internet USA (“Bank of Internet”), the across the nation brand of BofI Federal Bank, an accomplice of BofI Holding, Inc. (BOFI), was named MONEY’s Best Online Bank for 2016-2017. In Addition To, MONEY granted Best Checking Account to Bank of Internet’s Rewards Checking.

Cash broke down the 75 driving physical banks and online banks by buyer stores – in light of information from counseling firm Novantas – notwithstanding the 50 greatest credit unions. From just about 800 records, MONEY assembled 27,000 or more information focuses, tallying account terms, ATM systems, branch hours, portable application highlights, special credit rates, and different advantages.

Legg Mason Inc (NYSE:LM)

0

Headline: The organization has a place with Financial part and Asset Administration  industry. Shares of LM finished monday session in green in the midst of unstable exchanging. As

Exchanging Updates: Legg Mason Inc (NYSE:LM) went up 2.56% amid exchanging on 19/05/2016, with the organization’s shares hitting the cost close $30.88 on dynamic exchanging volume of 1.92M looked at its three months normal exchanging volume of 2.55M. The firm is currently exchanging -2.72% low its 20 day moving normal, SMA 50 of -1.02% and a SMA 200 of -3.92%. LM stock opened its last exchange at $30.27 and after moving in an extent of $30.27 to $31.07.

Stock enlisted one year high at $40.04% and the one year low of 24.93%. LM stock’s cost is currently -21.57% down from its 52-week high and 27.09% up from its 52-week low. LM institutional possession is held at 91.20% while insider proprietorship was 0.60%.

News: Legg Mason Inc., (LM), as of late announced an agreement with Shanda Group, Legg Mason’s driving shareholder, that incorporates a pledge to name Tianqiao Chen, Chairman and CEO of Shanda Group and an outstanding innovation business person in Asia, and Robert Chiu, President of Shanda Group and an official with 25 years of universal money related and innovation experience, to its Board of Directors by June 1, 2017. Mr. Chen will join the Board as the Vice Chairman. In that limit, Mr. Chen will lead Shanda’s endeavors to help Legg Mason in innovation advancement, notwithstanding business improvement and brand working in Asia, and China specifically. It is normal that Mr. Chen will likewise sit on the Nominating and Corporate Governance Committee, subject to fulfilling pertinent freedom prerequisites under relevant law or posting rules.

The assention thinks about Shanda Group acquiring extra shares of Legg Mason regular stock later on to expand its venture up to 15% of extraordinary normal stock, subject to economic situations and different contemplations. The assention likewise gives that Shanda Group won’t get more than 15% of the exceptional regular stock or start certain exchanges or activities checking intermediary requesting amid a three year time span.

In the wake of investing a noteworthyamount of energy with Legg Mason’s speculation partners, Shanda Group consented to put at any rate $500 million in venture items with Legg Mason partners. Shanda Group has likewise promised to make a significant commitment to Legg Mason’s beneficent establishment.

Shanda Group is Legg Mason’s driving shareholder, owning around 10% of the Company’s remarkable regular stock. Shanda Group is a worldwide private venture firm with a long haul speculation skyline, looking for interests in industry pioneers and really inventive advances and plans of action. It makes speculations crosswise over open market value, settled wage and products, private value and funding, and land.

Legg Mason will keep on working intimately with Shanda Group to influence its ability in innovation and to get to retail and institutional markets in Asia, two essential concentration regions of development for Legg Mason.

Joseph A. Sullivan, Chairman and CEO of Legg Mason, said: “We have been able to know the group at Shanda Group in the course of the most recent eight months, and trust Mr. Chen and Mr. Chiu will be superb assets for Legg Mason as individuals from our Board of Directors. As we work to improve the Company’s capacity to serve our worldwide shareholders, we discover their skill in vital zones of development to be important. Shanda’s arrangement to put a noteworthyamount of capital in the speculation results of Legg Mason partners illustrates, in an exceptionally important manner, Shanda’s conviction in Legg Mason.”

Tianqiao Chen, Chairman and CEO of Shanda Group, said: “Since putting resources into Legg Mason, we have unequivocally bolstered its system of offering shareholders enhanced decisions for speculation procedures, item sorts, topography, and customer get to that positions it for future development. The organization groups of Legg Mason and its venture partners have likewise inspired us with their speculation skill and demonstrated outcomes. Especially as innovation turns into an imperative segment of serving customers, we trust that we can offer Legg Mason an assistful point of view with our own understanding and assets. Shanda trusts Legg Mason is very much situated to appreciate proceeded with achievement, and is pleased to have the chance to additionally reinforce our association.”

Ashford Hospitality Prime Inc (NYSE:AHP)

0

Headline: The organization has a place with financial part and Hospitality REITs industry. Shares of AHP finished Monday session in green in the midst of unstable exchanging.

Exchanging Updates: AHP went up 1.50% amid exchanging on 19/05/2016, with the organization’s shares hitting the cost close $14.19 on dynamic exchanging volume of 163,402.00 looked at its three months normal exchanging volume of 183,934.00M. The firm is currently exchanging 5.32% low/over its 20 day moving normal, SMA 50 of 6.83% and a SMA 200 of 7.41%. AHP stock opened its last exchange at $14.07 and after moving in an extent of $13.99 to $14.22.

Stock enlisted one year high at $17.64% and the one year low of 8.37%. AHP stock’s cost is currently -19.56% down from its 52-week high and 69.53% up from its 52-week low. AHP institutional possession is held at 81.20% while insider proprietorship was 2.00%.

News:  Ashford Hospitality Prime, Inc. (AHP) (the “Organization” or “Ashford Prime”) proclaimed as of late that the United States Court of Appeals for the Fifth Circuit has rejected Sessa Capital (“Sessa’s”) allure of a government region court’s choice forbidding Sessa from requesting intermediaries and finding that the board had sensibly presumed that Sessa had neglected to conform to the Company’s local laws requiring consistence with material securities laws.

The trial court some time ago found that the Company had shown a considerable probability of accomplishment for its cases that Sessa and its chosen people damaged the Company’s local laws by neglecting to unveil their arrangements and recommendations for the Company and its benefits. The trial court in like manner announced that Sessa’s slate of competitors was invalid and ineligible to remain for race to the board and denied Sessa from naming applicants and requesting intermediaries for their benefit.

The Fifth Circuit has now rejected Sessa’s allure of the trial court’s request. The interests court reprimanded Sessa’s “strategic case choice” to look for cures on request that Sessa had positively declined to seek after in the trial court.